A clinical trial of GT90001 and Nivolumab (Opdivo®) combination therapy for the treatment of systemic therapy naïve patients with advanced hepatocellular carcinoma (HCC)
Latest Information Update: 13 Oct 2021
At a glance
- Drugs GT 90001 (Primary) ; Nivolumab (Primary)
- Indications Liver cancer
- Focus Therapeutic Use
- 13 Oct 2021 New trial record
- 11 Oct 2021 According to a Suzhou Kintor Pharmaceuticals media release, this study was approved by the National Medical Products Administration (NMPA) of China on October 9, 2021.